[HTML][HTML] Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease

A Chait, LJ Den Hartigh - Frontiers in cardiovascular medicine, 2020 - frontiersin.org
Adipose tissue plays essential roles in maintaining lipid and glucose homeostasis. To date
several types of adipose tissue have been identified, namely white, brown, and beige, that …

Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–mechanisms …

CC Low Wang, CN Hess, WR Hiatt, AB Goldfine - Circulation, 2016 - Am Heart Assoc
Cardiovascular disease remains the principal cause of death and disability among patients
with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying …

[HTML][HTML] Dyslipidemia in obesity: mechanisms and potential targets

B Klop, JWF Elte, M Castro Cabezas - Nutrients, 2013 - mdpi.com
Obesity has become a major worldwide health problem. In every single country in the world,
the incidence of obesity is rising continuously and therefore, the associated morbidity …

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

M Miller, NJ Stone, C Ballantyne, V Bittner, MH Criqui… - Circulation, 2011 - Am Heart Assoc
A long-standing association exists between elevated triglyceride levels and cardiovascular
disease*(CVD). 1, 2 However, the extent to which triglycerides directly promote CVD or …

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

E Ferrannini, RA DeFronzo - European heart journal, 2015 - academic.oup.com
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic
abnormalities. With time, multiple glucose-lowering medications are commonly required to …

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus

S Bolen, L Feldman, J Vassy, L Wilson… - Annals of internal …, 2007 - acpjournals.org
Background: As newer oral diabetes agents continue to emerge on the market, comparative
evidence is urgently required to guide appropriate therapy. Purpose: To summarize the …

Cardiovascular disease risk reduction by raising HDL cholesterol–current therapies and future opportunities

KM Ali, A Wonnerth, K Huber… - British journal of …, 2012 - Wiley Online Library
Since the first discovery of an inverse correlation between high‐density lipoprotein‐
cholesterol (HDL‐C) levels and coronary heart disease in the 1950s the life cycle of HDL, its …

Regulation of plasma triglycerides in insulin resistance and diabetes

HN Ginsberg, YL Zhang, A Hernandez-Ono - Archives of medical research, 2005 - Elsevier
Increased plasma levels of triglycerides (TG) in very low density lipoproteins (VLDL) are not
only common characteristics of the dyslipidemia associated with insulin resistance and type …

PPARs: therapeutic targets for metabolic disease

JP Berger, TE Akiyama, PT Meinke - Trends in pharmacological sciences, 2005 - cell.com
The three peroxisome-proliferator-activated receptor (PPAR) subtypes, PPAR-γ, PPAR-α
and PPAR-δ, are nuclear receptors that have been the focus of extensive research during …

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

RB Goldberg, DM Kendall, MA Deeg, JB Buse… - Diabetes …, 2005 - Am Diabetes Assoc
OBJECTIVE—Published reports suggest that pioglitazone and rosiglitazone have different
effects on lipids in patients with type 2 diabetes. However, these previous studies were …